Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

3/5/2021
BreakingClinical TrialCorneal
Glaukos’ Epi-on Keratoconus Therapy Meets Primary Endpoint in Phase III Trial
Glaukos’ Epi-on Keratoconus Therapy Meets Primary Endpoint in Phase III Trial

Glaukos announced Feb. 25 that its epi-on corneal cross-linking therapy for the treatment of keratoconus met its primary endpoint in a pivotal Phase III trial, demonstrating a statistically signifi...

3/5/2021
BreakingDry EyePharmaRegulation
US FDA Accepts NDA for Oyster Point’s Dry Eye Nasal Spray
US FDA Accepts NDA for Oyster Point’s Dry Eye Nasal Spray

Oyster Point Pharma announced March 2 that the US FDA had accepted its new drug application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The...

3/5/2021
BreakingCataractEarningsGlaucomaRetina
2020 Earnings Roundup: Glaukos, Aerie, and Two Others
2020 Earnings Roundup: Glaukos, Aerie, and Two Others

Glaukos reported Feb. 25 that its net sales for full year 2020 totaled $225 million, a decrease of 5 percent from $237.0 million in 2019. Q4-2020 net sales were $73.2 million, an 11 percent increas...

3/5/2021
BreakingDealsGlaucomaLaserRetina
Iridex, Topcon Join Forces in Glaucoma, Retinal Disease Treatment
Iridex, Topcon Join Forces in Glaucoma, Retinal Disease Treatment

Iridex and Topcon announced March 2 that the companies will collaborate worldwide on glaucoma and retinal disease treatments. Iridex will get in $19.5 million in cash from Topcon in the deal. Topco...

3/5/2021
BreakingPharmaRegulation
US FDA Accepts Eyenovia NDA for Fixed Combination Mydriatic Agent
US FDA Accepts Eyenovia NDA for Fixed Combination Mydriatic Agent

Eyenovia, of New York, announced March 2 that the US FDA had accepted the company’s new drug application (NDA) for MydCombi, a fixed combination mydriatic (pupil dilation) agent. MydCombi (phenylep...

3/5/2021
BreakingPharmaRegulation
Congress-Mandated Study Tackles Drug Waste in Single-Dose Vials
Congress-Mandated Study Tackles Drug Waste in Single-Dose Vials

A group of top US scientists studying drug waste in single-dose vials has recommended eliminating the 6 percent add-on payment made to physicians for Medicare Part B drugs and instead reimbursing p...

3/5/2021
BreakingGlaucomaLaserRetina
Ophthalmic Innovator George Marcellino, PhD, Dies
Ophthalmic Innovator George Marcellino, PhD, Dies

Longtime ophthalmic innovator George Marcellino, PhD, died unexpectedly Feb. 10, 2021, Iridex reported on its website. Dr. Marcellino had been serving as Iridex’ vice president of clinical affairs ...

3/5/2021
BreakingFundingLow Vision
$20 Million Gift to Fund Vision Care Research at University of Pittsburgh Medical Center
$20 Million Gift to Fund Vision Care Research at University of Pittsburgh Medical Center

The University of Pittsburgh Medical Center (UPMC) announced Feb. 25 that a $20 million gift from the Henry L. Hillman Foundation will fund vision care research and development. The gift was made t...

3/5/2021
BreakingMeeting
NEI, Southeast Asian Ophthalmic Groups Announce Meeting on Scientific Collaboration
NEI, Southeast Asian Ophthalmic Groups Announce Meeting on Scientific Collaboration

The National Eye Institute and Association of Southeast Asian Nations Ophthalmology Society, along with experts from several renowned institutions, will hold a free virtual symposium in mid-March t...

3/5/2021
BreakingRefractiveSurgical
Optimo’s Collaboration with Ansys Yields Surgical Planning Simulator for Treating Astigmatism
Optimo’s Collaboration with Ansys Yields Surgical Planning Simulator for Treating Astigmatism

Simulation innovators Optimo Medical AG and Ansys announced Feb. 23 that they have collaborated on a next-generation version of Optimo’s Optimeyes patient-specific surgical planning software for fa...

3/5/2021
AcquisitionsBreakingLaser
Boston Scientific Acquires Lumenis Urology, ENT Portfolio for $1.07 Billion
Boston Scientific Acquires Lumenis Urology, ENT Portfolio for $1.07 Billion

Boston Scientific of Marlborough, Massachusetts, announced March 3 that it was acquiring theLumenis surgical business for urology and otolaryngology (ears, nose, and throat, or ENT) from Baring Pri...

3/5/2021
BreakingFundingGene TherapyRetina
DTx Pharma Raises $100 Million in Series B Round to Advance its RNA Therapeutics Pipeline
DTx Pharma Raises $100 Million in Series B Round to Advance its RNA Therapeutics Pipeline

DTx Pharma, of San Diego, California, announced March 1 that it had completed a $100 million Series B financing. Arthur T. Suckow, PhD, chief executive officer of DTx Pharma, said the money would a...

Past News Stories

3/5/2021
BreakingFundingPharmaRetina
Oxular Raises $37 Million to Advance DME Candidate, Others
Oxular Raises $37 Million to Advance DME Candidate, Others

Oxular Limited announced March 1 that it had completed a $37 million financing led by European life sciences venture capital firm Forbion. The Oxford, England, company said the money would fund Pha...

3/5/2021
BreakingFundingGene TherapyRetina
Gene Therapy Developer SalioGen Closes $20 Million Series A Round
Gene Therapy Developer SalioGen Closes $20 Million Series A Round

SalioGen Therapeutics of Burlington, Massachusetts, announced March 1 that it had closed a $20 million Series A financing to support development of nonviral gene therapies. Proceeds will be used fo...

12/11/2020
BreakingCOVID-19Meeting
Market Scope Tracking Status of 2021 Ophthalmic Meetings
Market Scope Tracking Status of 2021 Ophthalmic Meetings

Market Scope is tracking the status of 2021 ophthalmic meetings as the world tries to recover from COVID-19. Here is the latest information: Organization Status Date Location More Information Glauc...

2/26/2021
BreakingPharmaRefractiveRegulation
Allergan Submits New Drug Application to US FDA for Presbyopia Drop
Allergan Submits New Drug Application to US FDA for Presbyopia Drop

Allergan, an AbbVie company, announced Feb. 25 that it had submitted a new drug application (NDA) to the US FDA for AGN-190584 (pilocarpine 1.25%) ophthalmic solution for symptoms of presbyopia. Th...

2/26/2021
BreakingCataractIOLRegulation
AcuFocus Submits US Premarket Approval Application for IC-8 Small Aperture IOL
AcuFocus Submits US Premarket Approval Application for IC-8 Small Aperture IOL

AcuFocus announced Feb. 23 that it had submitted a premarket approval (PMA) application to the US FDA for its IC-8 small aperture IOL. The IC-8 is an aspheric monofocal lens that features an embedd...

2/26/2021
BreakingCataractDry EyeEarningsRefractiveSurgical
2020 Earnings Roundup: Alcon, Bausch, Horizon, and Four More
2020 Earnings Roundup: Alcon, Bausch, Horizon, and Four More

Alcon reported Feb. 23 that full-year 2020 revenue totaled $6.8 billion, a decrease of 8 percent on a reported and constant currency basis, from $7.4 billion in 2019. The company said a substantial...

2/26/2021
BreakingGene TherapyRetina
Oculogenex Gene Therapy Startup Wins Winning Pitch Challenge—Retina
Oculogenex Gene Therapy Startup Wins Winning Pitch Challenge—Retina

Ophthalmologist Hema Ramkumar, MD, won the 2021 Winning Pitch Challenge—Retina, a virtual competition held Feb. 6. Ramkumar, a surgeon at Retina Consultants of Orange County, is the founder of Ocul...

2/26/2021
BreakingInstrumentsSurgical
Oertli Begins Construction of New Production and Logistics Factory
Oertli Begins Construction of New Production and Logistics Factory

Swiss ophthalmic surgical instrument maker Oertli announced Feb. 17 that it had started construction on a new factory at its location in Berneck. The three-story production and logistics building w...

2/26/2021
BreakingDry EyeSurgical
I-MED Pharma Shifts Surgical Portfolio to Keir to Focus on Dry Eye
I-MED Pharma Shifts Surgical Portfolio to Keir to Focus on Dry Eye

I-MED Pharma, of Montreal, Canada, announced Feb. 2 that Keir Surgical had taken ownership of its ophthalmic surgical portfolio. No financial details were given. I-MED said it would reinvest the pr...

2/26/2021
BreakingDealsGlaucomaPharma
UK’s Medicom Buys Generic Bimatoprost from Famar of Spain
UK’s Medicom Buys Generic Bimatoprost from Famar of Spain

Medicom Healthcare Limited, of the UK, announced Feb. 10 that it had acquired the product dossier of bimatoprost 0.3 mg/mL, 3ml, preservative-free eye drop solution from Spain’s Famar Health Care S...

2/26/2021
BreakingGene TherapyRetina
Ocugen Gene Therapy Candidate for RP, LCA Gains Orphan Status in EU
Ocugen Gene Therapy Candidate for RP, LCA Gains Orphan Status in EU

Ocugen announced Feb. 23that the European Commission had granted orphan medicinal product designation for its OCU400 gene therapy candidate for retinitis pigmentosa (RP) and Leber congenital amauro...

2/26/2021
BreakingPharmaRetina
Australia’s PYC Therapeutics Aims to Transition to US-Based Clinical-Stage Company  
Australia’s PYC Therapeutics Aims to Transition to US-Based Clinical-Stage Company

Australian company PYC Therapeutics, in a press release Feb. 22, cited progress in its transition to a US-based clinical-stage company, highlighting three RNA therapeutics in preclinical developmen...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 101 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2021 Market Scope, LLC. All Rights reserved.